Skip to content

Dialogues Clin Neurosci

ISSN 1294-8322; 1958-5969;

2 papers in the library · 4 citations · publishing 2025

Papers

Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?

Dialogues Clin Neurosci March 19, 2025 Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz et al. 2 citations

This theoretical paper explores whether psychedelic-assisted therapy could address comorbidities often accompanying Alzheimer's disease, such as depression, anxiety, and social withdrawal. The authors argue that psychedelics may promote neuroplasticity, reduce inflammation, and facilitate psychological breakthroughs that improve quality of life. They suggest that combining psychedelic compounds with psychotherapy might offer a novel approach to managing behavioral and psychological symptoms of dementia. The paper calls for further research into safety, dosing, and ethical considerations for this vulnerable population, noting that current evidence is preliminary and based largely on extrapolation from studies in other conditions.

Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).

Dialogues Clin Neurosci March 6, 2025 Paweł Holas, Justyna Kamińska, Marcin Zajenkowski 2 citations

A new scale, the Concerns and Openness towards Psychedelic Scale (COPS), was developed to measure societal attitudes toward clinical psychedelic use. The scale captures two dimensions: concerns about risks and openness to therapeutic benefits. It was validated through surveys and shows good psychometric properties, enabling researchers to assess public perspectives as psychedelic therapy gains attention in mental health treatment.